Bioject gets second deal with Amgen:
This article was originally published in Clinica
Bioject Medical Technologies has formed a second agreement with Amgen for Bioject's needle-free injection system for certain of Amgen's therapeutics. Bioject will get $1 million upfront, as well as development milestones and other payments. Amgen will get exclusive rights to the Portland, Oregon-based company's modified B2000 needle-free system. Under the terms of the new contract, Amgen's potential use of the needle-free systems is expanded. It also includes product licensing and commercial supply terms. The initial contract was signed in March 2000 and covered Bioject's Iject systems.
You may also be interested in...
Health ministers have called for more action on access to medicines, including a new EU work agenda, rebuilding Europe’s manufacturing capabilities, further action on pricing, and greater leeway for member states to mitigate drug shortages by restricting parallel exports.
China’s Bio-Thera Solutions has received approval from the country’s NMPA to launch a Phase I clinical study comparing the pharmacokinetics and safety of its proposed ustekinumab biosimilar to Johnson & Johnson’s blockbuster psoriasis drug Stelara, the latest in a string of the biotech company’s products to advance into clinical development.